Lu-Ann Murdoch
ARTICLES BY THIS AUTHOR
- 3/15/2022
An overview of Covifenz: The first plant-based COVID-19 vaccine approved in Canada
NACI suggests that, like Nuvaxovid, Covifenz may be an option for people unable or unwilling to receive an mRNA COVID-19 vaccine. - 3/13/2022
Patients worried about COVID risk and travel? CATMAT issues guidance statement
Travel may increase the risk of COVID-19, even while following recommended precautions. - 3/8/2022
Long-term cardiovascular risks are substantial in COVID-19 survivors
Survivors of COVID-19 are at increased risk of adverse cardiovascular outcomes even if they were not hospitalized during the acute phase of infection. - 3/7/2022
POP QUIZ: Sexually transmitted infections
Based on the PHAC’s Sexually transmitted and blood-borne infections: Guides for health professionals, all of the following are preferred or alternate treatment regimens for uncomplicated anogenital gonorrhea in adults and youth (≥ 9 years of age), EXCEPT for . . . - 3/6/2022
Effectiveness of COVID-19 vaccines and booster dose against the Omicron variant
Study examines effectiveness after two doses of Pfizer, AstraZeneca or Moderna vaccine and after a booster dose with Pfizer, AstraZeneca or Moderna vaccine. - 3/2/2022
Single-dose Janssen COVID-19 vaccine less effective than two-dose Pfizer vaccine
French study compares effectiveness of Janssen vaccine versus Pfizer vaccine against COVID-19–related hospitalization. - 2/28/2022
Health Canada considering Evusheld for COVID-19 pre-exposure prophylaxis
Single doses of tixagevimab and cilgavimab reduce incidence of symptomatic COVID-19 in at-risk adults for a six-month period. - 2/23/2022
Is combination antidepressant therapy better than antidepressant monotherapy?
Meta-analysis compares combinations of antidepressants with antidepressant monotherapy. - 2/23/2022
Pop quiz: Trulance for irritable bowel syndrome
All of the following statements about the new drug Trulance (plecanatide tablets) for irritable bowel syndrome are true, EXCEPT for . . . - 2/21/2022
Where will Nuvaxovid—the first protein subunit COVID-19 vaccine—fit in?
It will be an option for people unable or unwilling to receive an mRNA COVID-19 vaccine.
